Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

Abstract

These findings suggest measurable donepezil-mediated symptomatic benefits in cognition, global function, and daily living activities in patients with severe AD. The treatment effects support the importance of cholinesterase inhibition as a clinically relevant therapeutic option across the spectrum of AD.